375 related articles for article (PubMed ID: 30771532)
1. Isavuconazole MIC distribution of 29 yeast species responsible for invasive infections (2015-2017).
Desnos-Ollivier M; Bretagne S; Boullié A; Gautier C; Dromer F; Lortholary O;
Clin Microbiol Infect; 2019 May; 25(5):634.e1-634.e4. PubMed ID: 30771532
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of isavuconazole against clinically isolated yeasts from Chile.
Álvarez Duarte E; Salas V
Braz J Microbiol; 2020 Dec; 51(4):1801-1805. PubMed ID: 32638272
[TBL] [Abstract][Full Text] [Related]
3. Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.
Pfaller MA; Rhomberg PR; Messer SA; Jones RN; Castanheira M
Diagn Microbiol Infect Dis; 2015 Aug; 82(4):303-13. PubMed ID: 25986029
[TBL] [Abstract][Full Text] [Related]
4. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
5. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect.
Marcos-Zambrano LJ; Gómez A; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
Clin Microbiol Infect; 2018 Dec; 24(12):1343.e1-1343.e4. PubMed ID: 30025834
[TBL] [Abstract][Full Text] [Related]
6. EUCAST Susceptibility Testing of Isavuconazole: MIC Data for Contemporary Clinical Mold and Yeast Isolates.
Jørgensen KM; Astvad KMT; Hare RK; Arendrup MC
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910898
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.
Yamazaki T; Inagaki Y; Fujii T; Ohwada J; Tsukazaki M; Umeda I; Kobayashi K; Shimma N; Page MG; Arisawa M
Int J Antimicrob Agents; 2010 Oct; 36(4):324-31. PubMed ID: 20674282
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2608-16. PubMed ID: 23740727
[TBL] [Abstract][Full Text] [Related]
9.
Pfaller MA; Rhomberg PR; Wiederhold NP; Gibas C; Sanders C; Fan H; Mele J; Kovanda LL; Castanheira M
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061288
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
Astvad KMT; Hare RK; Arendrup MC
Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity.
Denis J; Ledoux MP; Nivoix Y; Herbrecht R
J Mycol Med; 2018 Mar; 28(1):8-14. PubMed ID: 29534853
[TBL] [Abstract][Full Text] [Related]
12. Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.
Sanglard D; Coste AT
Antimicrob Agents Chemother; 2016 Jan; 60(1):229-38. PubMed ID: 26482310
[TBL] [Abstract][Full Text] [Related]
13. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance.
Pfaller MA; Messer SA; Woosley LN; Jones RN; Castanheira M
J Clin Microbiol; 2013 Aug; 51(8):2571-81. PubMed ID: 23720791
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates.
Seifert H; Aurbach U; Stefanik D; Cornely O
Antimicrob Agents Chemother; 2007 May; 51(5):1818-21. PubMed ID: 17307977
[TBL] [Abstract][Full Text] [Related]
15. Fluconazole Resistance in Isolates of Uncommon Pathogenic Yeast Species from the United Kingdom.
Borman AM; Muller J; Walsh-Quantick J; Szekely A; Patterson Z; Palmer MD; Fraser M; Johnson EM
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182537
[TBL] [Abstract][Full Text] [Related]
16. Isavuconazole and nine comparator antifungal susceptibility profiles for common and uncommon Candida species collected in 2012: application of new CLSI clinical breakpoints and epidemiological cutoff values.
Castanheira M; Messer SA; Rhomberg PR; Dietrich RR; Jones RN; Pfaller MA
Mycopathologia; 2014 Aug; 178(1-2):1-9. PubMed ID: 24952015
[TBL] [Abstract][Full Text] [Related]
17. Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.
Shokohi T; Aslani N; Ahangarkani F; Meyabadi MF; Hagen F; Meis JF; Boekhout T; Kolecka A; Badali H
Microb Pathog; 2018 Feb; 115():353-357. PubMed ID: 29292174
[TBL] [Abstract][Full Text] [Related]
18. In vitro combination therapy with isavuconazole against Candida spp.
Katragkou A; McCarthy M; Meletiadis J; Hussain K; Moradi PW; Strauss GE; Myint KL; Zaw MH; Kovanda LL; Petraitiene R; Roilides E; Walsh TJ; Petraitis V
Med Mycol; 2017 Nov; 55(8):859-868. PubMed ID: 28204571
[TBL] [Abstract][Full Text] [Related]
19. APX001A
Arendrup MC; Chowdhary A; Astvad KMT; Jørgensen KM
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30104264
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test.
Nenoff P; Oswald U; Haustein UF
Mycoses; 1999; 42(11-12):629-39. PubMed ID: 10680439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]